ClinicalTrials.gg
Active, not recruitingNCT02655016Updated Mar 10, 2026Results posted

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3 interventional study of Niraparib and Placebo in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Active, not recruiting at 116 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
733
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
2nd of 44
733 · median 41
Started
2016
with 1 other
Phase 3
7 of 44
none open now
Primary completion
2019-05
later than 0 of 13 live
Registered
7th of 44
by date
Lead sponsor
11 of 44
Tesaro, Inc.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, reaches primary completion later than 0 of the 13 other live ones, and was the 7th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Ovarian Cancer
  • Niraparib
  • GSK3985771
  • Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP)Inhibitor
  • Homologous recombination deficiency (HRD)
  • HRD positive
  • PRIMA
  • PRIMA Clinical Trial
  • PRIMA Study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have diagnosed high-grade serous or endometrioid, or high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to Federation Internationale de Gynécologie et d'Obstétrique (FIGO) criteria.
  • Participants with inoperable Stage III and IV disease; All Stage IV participants with operable disease; Participants with stage III or IV disease treated with chemotherapy and interval debulking surgery; and Participants with stage III disease who have visible residual disease after primary debulking surgery.
  • Participants who have received intraperitoneal chemotherapy; All participants must have had more than or equal to (>=)6 and less than or equal to (\<=)9 cycles of platinum-based therapy; Participants must have had >=2 post-operative cycles of platinum-based therapy following interval debulking surgery; Participants must have physician assessed Complete response (CR) or Partial response (PR) after >=3 cycles of therapy; and Participants must have either Cancer antigen 125 (CA-125) in the normal range or CA-125 decrease by more than 90 percent(%) during their front-line therapy that is stable for at least 7 days (no increase more than (>)15% from nadir).
  • Participants must be randomized within 12 weeks of the first day of the last cycle of chemotherapy.
  • All participants must agree to undergo central tumor HRD testing.
  • Participants of must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin [hCG]) within 7 days prior to receiving the first dose of study treatment.

Exclusion criteria

Exclusion criteria:

  • Participant has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancer.
  • Participants with Stage III disease who have had complete cytoreduction (no visible residual disease) after primary debulking surgery.
  • Participant has undergone more than two debulking surgeries for the study disease.
  • Participant is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for up to 180 days after the last dose of study treatment.
  • Participant has a known to the components of niraparib or its .
  • Participant has received prior treatment with a known PARP inhibitor or has participated in a study where any treatment arm included administration of a known PARP inhibitor.
  • Participant is to receive bevacizumab as maintenance treatment.
  • Participant has had therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  • Participant has had any known >=Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted >4 weeks.
  • Participant has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results or interfere with the participation for the full duration of the study treatment, including:

    1. Participant received a transfusion ( or red blood cells) within 2 weeks of the first dose of study treatment.
    2. Participant received colony-stimulating factors (e.g., granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment.
  • Participant has been diagnosed and/or treated for invasive cancer less than 5 years prior to study enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
733 participants (actual)

Study arms

  • Experimental
    Participants receiving Niraparib

    Drug: Niraparib

  • Placebo comparator
    Participants receiving Placebo

    Drug: Placebo

Interventions

  • Niraparib will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Progression free survival was defined as the time from the date of treatment randomization to the date of first documentation of disease progression or death due to any cause in the absence of documented progression, whichever occurs first. It was assessed by the blinded independent central review (BICR). Median and 95% confidence interval (CI) are presented.

    Time frame: Up to 34 months

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of death by any cause. Median and 95% CI are presented for overall survival interim analysis.

    Time frame: Up to 34 months

  2. Time to First Subsequent Therapy (TFST)

    Time to first subsequent therapy was defined as the time from the date of randomization to the date of the first subsequent anti-cancer therapy or death, whichever occurs first. Median and 95% CI are presented.

    Time frame: Up to 34 months

  3. Progression-Free Survival-2 (PFS2)

    PFS2 was defined as the time from the date of randomization to the date of progression on the next anti-cancer therapy following study treatment or death by any cause, whichever occurs first. Median and 95% CI are presented.

    Time frame: Up to 34 months

  4. Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)

    FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as (sum of item scores)\*8 divided by (number of items answered). The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to Week 24

  5. Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score

    The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to Week 24

  6. Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

    EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \[average score minus 1\] divided by 3\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher ("better") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to Week 24

  7. Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30

    EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. A global health status/QoL scale had total 2 items. Each global health status/QoL scales score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 6\*100). The global health status/QoL scales range in score from 0 to 100. Higher score represents a higher ("better") level of health status/QoL. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to Week 24

  8. Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30

    EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher ("worse") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to Week 24

  9. Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)

    EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal \[GI\] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \[average score minus 1\] divided by 3\*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher ("better") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to 34 months

  10. Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28

    EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher ("worse") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

    Time frame: Baseline (Day 1, Pre-dose) and Up to 34 months

Other outcomes

  1. Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE

    An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.

    Time frame: Up to 34 months

  2. Area Under the Curve (AUC) From 0 to the Last Quantifiable Concentration (AUC[0-last])

    Blood samples were planned to be collected for assessment of AUC(0-last).

    Time frame: Up to 34 months

  3. Peak Plasma Concentration (Cmax)

    Blood samples were planned to be collected for assessment of Cmax.

    Time frame: Up to 34 months

  4. Number of Participants With Positive HRD Test

    Number of participants with positive HRD test was planned to be assessed.

    Time frame: Up to 34 months

07

Results

Posted Jun 11, 2020

Participant flow

In this double-blind, randomized, placebo-controlled study, participants with stage III or IV ovarian cancer were randomized to receive either niraparib or placebo in 2:1 ratio. The results presented are based on the primary analysis up to month 34. Data collection is still on-going and additional results will be provided after study completion (7 years).

Participant flow — Overall Study
MilestonePlaceboNiraparib
Started246487
Received study treatment244484
Ongoing with treatment in the study69177
Completed191397
Not completed5590
Withdrew: Disease progression64
Withdrew: Site closed01
Withdrew: Death3048
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject1836

Outcome measures

PrimaryProgression Free Survival

Progression free survival was defined as the time from the date of treatment randomization to the date of first documentation of disease progression or death due to any cause in the absence of documented progression, whichever occurs first. It was assessed by the blinded independent central review (BICR). Median and 95% confidence interval (CI) are presented.

Time frame:
Up to 34 months
Reported as:
Median · Months
Progression Free Survival
MonthsPlaceboNiraparib
Progression Free Survival8.2 (7.3 to 8.5)13.8 (11.5 to 14.9)
Statistical analysis
  • Placebo vs Niraparib · Log Rank · p = <0.0001 (p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and homologous recombination deficiency (HRD) status.) · Hazard ratio (hr): 0.62 · 95% CI 0.502 to 0.755If hazard ratio was found to be \<1 then niraparib can be considered as superior to placebo.
SecondaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of death by any cause. Median and 95% CI are presented for overall survival interim analysis.

Time frame:
Up to 34 months
Reported as:
Median · Months
Overall Survival
MonthsPlaceboNiraparib
Overall SurvivalNA (25.0 to NA)30.3 (30.3 to NA)
Statistical analysis
  • Placebo vs Niraparib · Log Rank · p = 0.1238 (p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.) · Hazard ratio (hr): 0.70 · 95% CI 0.442 to 1.106If hazard ratio was found to be \<1 then niraparib can be considered as superior to placebo.
SecondaryTime to First Subsequent Therapy (TFST)

Time to first subsequent therapy was defined as the time from the date of randomization to the date of the first subsequent anti-cancer therapy or death, whichever occurs first. Median and 95% CI are presented.

Time frame:
Up to 34 months
Reported as:
Median · Months
Time to First Subsequent Therapy (TFST)
MonthsPlaceboNiraparib
Time to First Subsequent Therapy (TFST)12.0 (10.3 to 13.9)18.6 (15.8 to 24.7)
Statistical analysis
  • Placebo vs Niraparib · Log Rank · p = 0.0001 (p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.) · Hazard ratio (hr): 0.65 · 95% CI 0.521 to 0.802If hazard ratio was found to be \<1 then niraparib can be considered as superior to placebo.
SecondaryProgression-Free Survival-2 (PFS2)

PFS2 was defined as the time from the date of randomization to the date of progression on the next anti-cancer therapy following study treatment or death by any cause, whichever occurs first. Median and 95% CI are presented.

Time frame:
Up to 34 months
Reported as:
Median · Months
Progression-Free Survival-2 (PFS2)
MonthsPlaceboNiraparib
Progression-Free Survival-2 (PFS2)NA (NA to NA)27.2 (25.3 to NA)
Statistical analysis
  • Placebo vs Niraparib · Log Rank · p = 0.2242 (p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.) · Hazard ratio (hr): 0.81 · 95% CI 0.577 to 1.139If hazard ratio was found to be \<1 then niraparib can be considered as superior to placebo.
SecondaryChange From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)

FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as (sum of item scores)\*8 divided by (number of items answered). The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)
Scores on a scalePlaceboNiraparib
Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)-0.3 ± 0.22-0.4 ± 0.15
SecondaryChange From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score

The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score
Scores on a scalePlaceboNiraparib
Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score0.005 ± 0.00660.016 ± 0.0046
SecondaryChange From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \[average score minus 1\] divided by 3\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher ("better") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Scores on a scalePlaceboNiraparib
Physical Functioning, n=244,4792.119 ± 0.81312.013 ± 0.5735
Role Functioning, n=244,4792.341 ± 1.24271.590 ± 0.8810
Emotional Functioning, n=243,478-0.011 ± 1.1218-0.870 ± 0.7685
Cognitive Functioning, n=243,478-0.020 ± 1.2105-0.842 ± 0.7952
Social Functioning, n=243,4785.557 ± 1.24494.445 ± 0.8633
SecondaryChange From Baseline in Global Health Status/QoL of EORTC-QLQ-C30

EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. A global health status/QoL scale had total 2 items. Each global health status/QoL scales score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 6\*100). The global health status/QoL scales range in score from 0 to 100. Higher score represents a higher ("better") level of health status/QoL. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30
Scores on a scalePlaceboNiraparib
Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C301.177 ± 1.00051.009 ± 0.6898
SecondaryChange From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30

EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher ("worse") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30
Scores on a scalePlaceboNiraparib
Fatigue, n=243,479-0.082 ± 1.23940.085 ± 0.8363
Nausea/Vomiting, n=244,4791.673 ± 0.75953.115 ± 0.4828
Pain, n=244,480-0.195 ± 1.22740.765 ± 1.0166
Dyspnea, n=244,4790.644 ± 1.35921.347 ± 0.8518
Insomnia, n=244,4792.195 ± 1.98823.478 ± 1.2791
Appetite Loss, n=8,30-0.827 ± 4.3987-0.395 ± 2.3195
Constipation, n=244,478-1.147 ± 1.57936.356 ± 1.0446
Diarrhea, n=8,309.335 ± 3.8667-3.340 ± 2.0136
Financial Difficulties, n=243,475-5.058 ± 1.2978-3.356 ± 0.9276
SecondaryChange From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)

EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal \[GI\] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus \[average score minus 1\] divided by 3\*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher ("better") level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to 34 months
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)
Scores on a scalePlaceboNiraparib
Body Image, n=244,47510.069 ± 1.48208.488 ± 1.0138
Sexuality, n=240,4713.257 ± 1.18863.625 ± 0.8004
Attitude to disease/Treatment, n=244,47512.216 ± 1.325713.660 ± 0.9309
SecondaryChange From Baseline in Symptoms Scale of EORTC-QLQ-OV28

EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly (\[average score minus 1\] divided by 3\*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher ("worse") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).

Time frame:
Baseline (Day 1, Pre-dose) and Up to 34 months
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28
Scores on a scalePlaceboNiraparib
Abdominal/GI, n=244,4810.832 ± 0.81102.185 ± 0.5703
Peripheral Neuropathy, n=244,480-9.629 ± 1.3219-8.217 ± 0.9295
Hormonal/Menopausal Symptoms, n=244,480-2.521 ± 1.30741.501 ± 0.8803
Other Chemotherapy Side Effects, n=244,480-3.023 ± 0.8358-2.219 ± 0.5581
Hair Loss, n=242,477-20.743 ± 1.3690-23.363 ± 0.9821
Other pre-specifiedNumber of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE

An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.

Time frame:
Up to 34 months
Reported as:
Count of participants · Participants
Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE
ParticipantsPlaceboNiraparib
Any non-SAE223478
Any SAE32156
Other pre-specifiedArea Under the Curve (AUC) From 0 to the Last Quantifiable Concentration (AUC[0-last])

Blood samples were planned to be collected for assessment of AUC(0-last).

Time frame:
Up to 34 months

No measurements were reported for this outcome.

Other pre-specifiedPeak Plasma Concentration (Cmax)

Blood samples were planned to be collected for assessment of Cmax.

Time frame:
Up to 34 months

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Positive HRD Test

Number of participants with positive HRD test was planned to be assessed.

Time frame:
Up to 34 months

No measurements were reported for this outcome.

Adverse events

Collected over Serious adverse events (SAEs) and non-SAEs were reported from start of study treatment (Day 1) and up to month 34 (primary analysis). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo31/244 (12.7%)32/244 (13.1%)223/244 (91.4%)
Niraparib48/484 (9.9%)156/484 (32.2%)478/484 (98.8%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventPlaceboNiraparib
ThrombocytopeniaBlood and lymphatic system disorders0/24459/484
AnaemiaBlood and lymphatic system disorders0/24427/484
Platelet count decreasedInvestigations0/24420/484
Small intestinal obstructionGastrointestinal disorders5/24414/484
OverdoseInjury, poisoning and procedural complications3/2448/484
NeutropeniaBlood and lymphatic system disorders0/2446/484
Intestinal obstructionGastrointestinal disorders1/2445/484
PneumonitisRespiratory, thoracic and mediastinal disorders0/2444/484
Abdominal painGastrointestinal disorders2/2441/484
SubileusGastrointestinal disorders2/2440/484
Most frequent other events
Showing 10 of 738
Most frequent other events
EventPlaceboNiraparib
AnaemiaBlood and lymphatic system disorders43/244306/484
NauseaGastrointestinal disorders67/244278/484
ThrombocytopeniaBlood and lymphatic system disorders9/244210/484
ConstipationGastrointestinal disorders46/244189/484
FatigueGeneral disorders72/244168/484
Abdominal painGastrointestinal disorders74/244105/484
Platelet count decreasedInvestigations3/244129/484
NeutropeniaBlood and lymphatic system disorders16/244126/484
HeadacheNervous system disorders36/244126/484
InsomniaPsychiatric disorders35/244119/484

Baseline characteristics

Baseline characteristics were presented for all randomized participants including 5 randomized participants who never received treatment (4-Screen failure and 1-Withdrew consent).

Age, Continuous
Age, Continuous(Years)PlaceboNiraparibTotal
Mean61.3 ± 10.3961.1 ± 10.7961.2 ± 10.65
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNiraparibTotal
Female246487733
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboNiraparibTotal
White219436655
Black21012
Asian111425
American Indian or Alaska Native011
Native Hawaiian or other Pacific Islander011
Unknown142539
08

Study locations

116 sites
  • GSK Investigational Site
    Tempe, Arizona 85284, United States
  • GSK Investigational Site
    Tucson, Arizona 85710, United States
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    San Francisco, California 94118, United States
  • GSK Investigational Site
    Santa Rosa, California 95403, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Savannah, Georgia 31404, United States
  • GSK Investigational Site
    Geneva, Illinois 60555, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46237, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46260, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Baltimore, Maryland 21215-5271, United States
  • GSK Investigational Site
    Rockville, Maryland 20910, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 49503, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55433, United States
  • GSK Investigational Site
    Springfield, Missouri 97477, United States
  • GSK Investigational Site
    Neptune City, New Jersey 07753, United States
  • GSK Investigational Site
    Harrison, New York 10604, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Rochester, New York 14620, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7570, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Columbus, Ohio 43210, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74146, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Sioux Falls, South Dakota 57105, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    The Woodlands, Texas 77380, United States
  • GSK Investigational Site
    Tyler, Texas 75701, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84112, United States
  • GSK Investigational Site
    Kennewick, Washington 99336, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Spokane, Washington 99202, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Bonheiden, 2820, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Hasselt, 3500, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Libramont, 6800, Belgium
  • GSK Investigational Site
    Namur, 5000, Belgium
  • GSK Investigational Site
    Aalborg, 9000, Denmark
  • GSK Investigational Site
    Copenhagen, 2100, Denmark
  • GSK Investigational Site
    Herlev, 2730, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Oulu, 90029, Finland
  • GSK Investigational Site
    Tampere, 33521, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Aachen, 52074, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Essen, 45136, Germany
  • GSK Investigational Site
    Fürth, 90766, Germany
  • GSK Investigational Site
    Göttingen, 37075, Germany
  • GSK Investigational Site
    Heidelberg, 69120, Germany
  • GSK Investigational Site
    Hildesheim, 31134, Germany
  • GSK Investigational Site
    Mannheim, 68167, Germany
  • GSK Investigational Site
    München, 81377, Germany
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dunmore RoadWaterford, Ireland
  • GSK Investigational Site
    Galway, H91 YR71, Ireland
  • GSK Investigational Site
    Haifa, 38100, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Lecce, 73100, Italy
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Modena, 41100, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Oslo, 0310, Norway
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Barcelona, 8035, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Donostia / San Sebastian, 20014, Spain
  • GSK Investigational Site
    Elche Alicante, 03203, Spain
  • GSK Investigational Site
    Girona, 17007, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Seville, 41013, Spain
  • GSK Investigational Site
    Seville, 41014, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain

Showing the first 100 of 116 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Perez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonzalez-Martin A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. PubMed 39284381 ↗
  • Shahin MS, Lorusso D, Backes FJ, Barretina-Ginesta MP, O'Malley DM, Forget F, Pothuri B, Hietanen S, McCormick CC, Abadie-Lacourtoisie S, O'Cearbhaill RE, Heitz F, Moore RG, Amit A, Willmott LJ, Perez MR, Burger RA, Redondo A, Chase DM, Romero I, Moore KN, Vergote I, Cloven N, Haslund CA, Graybill WS, Bergamini A, Berton D, Braicu EI, Lim JT, Golembesky AK, Shtessel L, Monk BJ, Gonzalez-Martin A. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2026 Jul 1;211:79-88. doi: 10.1016/j.ygyno.2026.06.010. Online ahead of print. PubMed 42385609 ↗
  • Monk BJ, Romero I, Graybill W, Churruca C, O'Malley DM, Knudsen AO, Yap OWS, Baurain JF, Rose PG, Denys H, Ghamande S, Pisano C, Fabbro M, Braicu EI, Calvert PM, Amit A, Prendergast E, Taylor A, Kheibarshekan L, Zhang ZY, Zajic S, Jewell RC, Gupta D, Gonzalez-Martin A. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer. Clin Ther. 2024 Aug;46(8):612-621. doi: 10.1016/j.clinthera.2024.06.001. Epub 2024 Jul 16. PubMed 39019698 ↗
  • Vulsteke C, Chambers SK, Perez MJR, Chan JK, Raaschou-Jensen N, Zhuo Y, Lorusso D, Herzog TJ, de la Motte Rouge T, Thomes Pepin JA, Braicu EI, Chen LM, Levy T, Barter JF, Pilar Barretina-Ginesta M, Joosens E, York W, Malinowska IA, Gonzalez-Martin A, Monk BJ. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. Eur J Cancer. 2024 Sep;208:114157. doi: 10.1016/j.ejca.2024.114157. Epub 2024 Jun 10. PubMed 39013265 ↗
  • Graybill WS, Pardo Burdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, Gonzalez-Martin A. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Int J Gynecol Cancer. 2024 Jul 1;34(7):1041-1050. doi: 10.1136/ijgc-2024-005356. PubMed 38950925 ↗
  • Valabrega G, Pothuri B, Oaknin A, Graybill WS, Sanchez AB, McCormick C, Baurain JF, Tinker AV, Denys H, O'Cearbhaill RE, Hietanen S, Moore RG, Knudsen AO, de La Motte Rouge T, Heitz F, Levy T, York W, Gupta D, Monk BJ, Gonzalez-Martin A. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024 Aug;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Epub 2024 Jun 3. PubMed 38833992 ↗
  • Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary. Future Oncol. 2024;20(22):1531-1544. doi: 10.2217/fon-2023-0782. Epub 2024 Mar 19. PubMed 38501262 ↗
  • Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Maenpaa J, Gupta D, Bacque E, Li Y, Compton N, Antonova J, Monk BJ, Gonzalez-Martin A. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024 May;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Epub 2024 Feb 6. PubMed 38325276 ↗
  • Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. PubMed 37263896 ↗
  • Barretina-Ginesta MP, Monk BJ, Han S, Pothuri B, Auranen A, Chase DM, Lorusso D, Anderson C, Abadie-Lacourtoisie S, Cloven N, Braicu EI, Amit A, Redondo A, Shah R, Kebede N, Hawkes C, Gupta D, Woodward T, O'Malley DM, Gonzalez-Martin A. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. Ther Adv Med Oncol. 2022 Sep 22;14:17588359221126149. doi: 10.1177/17588359221126149. eCollection 2022. PubMed 36172173 ↗
  • O'Cearbhaill RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dorum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, Gonzalez-Martin A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. Epub 2022 May 9. PubMed 35550709 ↗
  • Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Perez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. PubMed 31562799 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in May 2019, 34 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 34 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2015
First posted
Jan 13, 2016
StartActual
Jul 11, 2016
Primary completionActual
May 17, 2019
CompletionEst.
May 29, 2026
Results first posted
Jun 11, 2020
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02655016
Lead sponsor
Tesaro, Inc.
Collaborators
Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT), Myriad Genetics, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2016
Start date
Jul 11, 2016
Primary completion
May 17, 2019
Completion
May 29, 2026 (estimated)
Results posted
Jun 11, 2020
Last update
Mar 10, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion